Contacts

US Pharma Development Veteran Dr. Richard Malamut Joins the Medical Advisory Board of MedinCell

January 28, 2020

“Clinical development will become a significant part of MedinCell’s expenses and will define the time to market of our products. Bringing on board Richard, with his wealth of knowledge in pharmaceutical development, clinical trial strategy and design optimization will be instrumental to our performance,” states Christophe Douat, CEO of MedinCell.

Composed of recognized international experts, the Medical Advisory Board’s (MAB) mission is to advise on medical matters, portfolio extension, and product development strategies. The MAB meets at least quarterly to evaluate programs progress and also provides ad hoc guidance. Richard will enrich the Board’s remit with his learned experience in drug development, in particular in the field of the Central Nervous System (CNS) and pain.

Richard Malamut is currently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals. Previously, from 2013 to 2016, he was the Senior Vice President of Global Clinical Development for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities at Teva Pharmaceuticals. He also has served as Chief Medical Officer for Braeburn Pharmaceuticals and Avanir Pharmaceuticals. Prior to that, he had multiple roles with increasing responsibilities at Bristol-Myers and AstraZeneca focused on early clinical development and translational medicine.

Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in Neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease.

“My experience in translational medicine and clinical development has equipped me with a unique perspective to provide guidance for MedinCell’s growing portfolio,” stated Dr. Malamut. “I am thrilled to be able to contribute to a company with a deep commitment to patients.”

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.